Serplulimab With Chemotherapy in Extensive-Stage SCLC

Abstract

There is a need to synthesize the available data from the various recently completed clinical trials, and an individual patient data network meta-analysis would assist clinicians to determine which noninvasive respiratory support strategy, if any, is most effective. Furthermore, it is increasingly recognized that the definition of AHRF is broad and captures many different groups of patients. While COVID-19 represents a single disease process, there is increasing evidence that genotypes 13,14 and phenotypes 15 exist and can affect outcome. There is a clear need to incorporate these phenotypes in AHRF and COVID-19-induced AHRF into future trial designs, to determine which subgroups of patients are most likely to derive benefit (or harm) from these therapies.The available evidence suggests that the initial choice of supplemental oxygen therapy for patients with COVID-19-related AHRF does not influence mortality. This will provide some reassurance for clinicians in times of reduced availability of certain noninvasive respiratory support strategies during surges in COVID-19 hospitalizations. Particular attention should be given to the potential for complications with each approach, as well as patient preference and tolerance of the selected therapy.

Advances in immune checkpoint inhibitors therapy for small cell lung cancer

“…42 The researcher speculated that the recruited individuals may have other tissue types of lung cancer that were more responsive to immunotherapy, which could affect the study results. 42 To treat SCLC, there were no randomized controlled trials that directly contrast the effectiveness of PD-1 inhibitors and PD-L1 inhibitors. 42 The use of ICIs in SCLC for first-line treatment is still confined to combination chemotherapy.…”

“…42 To treat SCLC, there were no randomized controlled trials that directly contrast the effectiveness of PD-1 inhibitors and PD-L1 inhibitors. 42 The use of ICIs in SCLC for first-line treatment is still confined to combination chemotherapy. New combination modalities of ICIs are being investigated to improve the benefit of ICIs in the treatment of SCLC.…”

“…The ASTRUM‐005 study population was contentious and differs from SCLC patients in the United States. The ASTRUM‐005 research comprised approximately two‐thirds of the Asian population and a higher number of nonsmokers than other clinical studies, limiting direct comparisons between trials 42 . The researcher speculated that the recruited individuals may have other tissue types of lung cancer that were more responsive to immunotherapy, which could affect the study results 42 .…”

“…The ASTRUM‐005 research comprised approximately two‐thirds of the Asian population and a higher number of nonsmokers than other clinical studies, limiting direct comparisons between trials 42 . The researcher speculated that the recruited individuals may have other tissue types of lung cancer that were more responsive to immunotherapy, which could affect the study results 42 . To treat SCLC, there were no randomized controlled trials that directly contrast the effectiveness of PD‐1 inhibitors and PD‐L1 inhibitors 42 …”

“…It is necessary for us to continue the later studies to obtain more positive results. However, some scholars believed that the limitations of the study led to the exact action of Serplulimab still needing to be refined 42 . The ASTRUM‐005 study population was contentious and differs from SCLC patients in the United States.…”